



**SUPPLEMENTARY FIGURES**



**Supplementary Figure 1. Survival analysis and prognostic value of ADAM15 between the high and low expression groups.** (A) Kaplan-Meier survival analysis of OS in HCC. (B) Kaplan-Meier survival analysis of Relapse Free Survival (RFS) in HCC. (C) Kaplan-Meier survival analysis of Progression Free Survival (PFS) in HCC. (D) Kaplan-Meier survival analysis of Disease Free Survival (DSS) in HCC.



**Supplementary Figure 2. The expression of ADAM15 in different immune infiltration cells between liver cancer tissues and paired normal tissues.** (A) The expression of ADAM15 in T cells CD4 naive, NK cells activated, Monocytes, Macrophages M1 and Macrophages M2 in liver cancer tissues. (B) The expression of ADAM15 in T cells CD4 naive, NK cells activated, Monocytes, Macrophages M1 and Macrophages M2 between liver cancer tissues and corresponding normal tissues. (C) The expression of ADAM15 in B naive cells, CD8 T cells, Macrophages M0, Dendritic cells and Neutrophils in liver cancer tissues. (D) The expression of ADAM15 in B naive cells, CD8 T cells, Macrophages M0, Dendritic cells and Neutrophils between liver cancer tissues and paired normal tissues.